Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 1, 2015, Pages 61-68

  Vanneste, L ^a   Wolter, P ^a   Van Den Oord, J J ^a   Stas, M ^a   Garmyn, M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; DACARBAZINE; ERYTHROMYCIN; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; INTERFERON; KERATOLYTIC AGENT; MOMETASONE FUROATE; SALICYLIC ACID; STEROID; SUNSCREEN; TRAMETINIB; UREA DERIVATIVE; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; SULFONAMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CRYOTHERAPY; ECZEMA; FACE ERYTHEMA; FEMALE; GENE MUTATION; HAIR DISEASE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; KERATOACANTHOMA; KERATOSIS; MALE; METASTATIC MELANOMA; MIDDLE AGED; NIPPLE; PAPULE; PHOTOTOXICITY; PREVALENCE; PROSPECTIVE STUDY; SCALP; SEBORRHEIC DERMATITIS; SKIN BIOPSY; SKIN CARCINOMA; SKIN CYST; SKIN MANIFESTATION; SKIN PAPILLOMA; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; VERRUCOUS PAPILLOMA; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DERMATITIS, PHOTOTOXIC; ERYTHEMA; GENETICS; HAND-FOOT SYNDROME; MELANOMA; PAPILLOMA; PATHOLOGY; SECONDARY; SKIN DISEASE; SKIN NEOPLASMS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ALOPECIA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DERMATITIS, PHOTOTOXIC; ECZEMA; ERYTHEMA; FACIAL DERMATOSES; FEMALE; HAND-FOOT SYNDROME; HUMANS; IMIDAZOLES; INDOLES; KERATOACANTHOMA; MALE; MELANOMA; MIDDLE AGED; OXIMES; PAPILLOMA; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84919871618     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12449     Document Type: Article

References (19)

1. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
2. Hauschild A, Grob JJ, Demidov LV, et al,. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
3. Bello DM, Ariyan CE, Carvajal RD,. Melanoma mutagenesis and aberrant cell signaling. Cancer control 2013; 20: 261-281.
4. Denning MF,. Specifying protein kinase C functions in melanoma. Pigment cell Melanoma Res 2012; 25: 466-476.
5. Denning M,. PKC isozymes and skin cancer. In, Kazanietz MGG, ed. Protein kinase C in cancer signaling and therapy, 1st edn. Springer, Current Cancer Research, Humana Press, 2010; 323-347.
6. Anforth R, Fernandez- Peñas P, Long GV,. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013; 14: e11-e18.
7. Sinha R, Edmonds K, Newton-Bishop JA, Gore ME, Larkin J, Fearfield L,. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012; 167: 987-994.
8. Ravnan MC, Matalka MS,. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther 2012; 34: 1474-1486.
9. Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J,. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol 2013; 27: 11-18.
10. Mattei P, Allori-Palli MB, Kraft S, Lawrence DP, Flaherty KP, Kimball AB,. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol 2013; 24: 530-537.
11. Chu EY, Wanat KA, Miller CJ, et al,. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 2012; 67: 1265-1272.
12. Boussemart L, Routier E, Mateus C, et al,. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013; 24: 1691-1697.
13. Oberholzer PA, Kee D, Dziunycz P, et al,. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-321.
14. Anforth R, Blumetti TC, Mohd Affandi A, Fernandez-Peñas P,. Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J Clin Oncol 2012; 30: e165-e167.
15. Flaherty KT, Infante JR, Daud A, et al,. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
16. Gelot P, Dutartre H, Khammari A, et al,. Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol 2013; 22: 297-298.
17. Boyd KP, Vincent B, Andea A, Conry RM, Hughey LC,. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol 2012; 67: 1375-1379.
18. Sibaud V, Delord JP, Chevreau C, Gangloff D, Garrido-Stowhass I,. Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology. Ann Chir Plast Esth 2012; 57: 106-113.
19. Zimmer L, Hillen U, Livingstone E, et al,. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375-2383.